IMTX
Immatics N.V.
NASDAQ · Healthcare · Biotechnology · DE
$9.56
+1.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 41.7M | 48.3M | 155.8M | 54.0M | 172.8M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 41.7M | 48.3M | 155.8M | 54.0M | 172.8M |
| Operating Expenses | |||||
| R&D Expense | 218.4M | 183.8M | 148.1M | 118.7M | 106.8M |
| SG&A Expense | 54.8M | 51.2M | 46.4M | 38.2M | 36.1M |
| General & Admin Expense | 54.8M | 51.2M | 46.4M | 38.2M | 36.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (4.7M) | (4.7M) | (78.0K) | (1.1M) | (26.0K) |
| Total Operating Expenses | 268.5M | 230.3M | 194.4M | 155.7M | 142.9M |
| Cost and Expenses | 268.5M | 230.3M | 194.4M | 155.7M | 142.9M |
| Operating Income (EBIT) | (226.8M) | (182.0M) | (38.6M) | (101.7M) | 30.0M |
| Non-Operating | |||||
| Interest Income | 14.3M | 17.2M | 25.0M | 13.8M | 2.5M |
| Interest Expense | 868.0K | 946.0K | 886.0K | 831.0K | 1.0M |
| Net Interest Income | 13.5M | 16.2M | 24.1M | 13.0M | 1.4M |
| Other Non-Op Income/Expense | 20.0M | (16.4M) | 60.0M | 4.7M | 12.1M |
| Non-Operating Income (excl Interest) | (20.9M) | 15.5M | (60.8M) | (5.6M) | (13.1M) |
| EBT (Pre-Tax Income) | (206.8M) | (198.4M) | 21.3M | (97.0M) | 42.0M |
| Income Tax Expense | (215.0K) | (2.0M) | 6.1M | (2.3M) | 14.3M |
| Bottom Line | |||||
| Net Income | (206.5M) | (196.4M) | 15.2M | (94.6M) | 27.7M |
| Earnings from Cont. Ops | (206.5M) | (196.4M) | 15.2M | (94.6M) | 27.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (206.5M) | (196.4M) | 15.2M | (94.6M) | 27.7M |
| Per Share | |||||
| Basic EPS | ($1.59) | ($1.54) | $0.14 | ($1.18) | $0.56 |
| Diluted EPS | ($1.59) | ($1.54) | $0.14 | ($1.18) | $0.55 |
| Revenue Per Share | $0.31 | $0.39 | $1.46 | $0.67 | $2.58 |
| Shares | |||||
| Basic Shares Outstanding | 136.7M | 122.3M | 106.8M | 80.5M | 67.0M |
| Diluted Shares Outstanding | 136.7M | 122.3M | 106.8M | 80.5M | 68.2M |
| Profitability Metrics | |||||
| EBITDA | (193.8M) | (185.1M) | 34.5M | (88.9M) | 50.0M |
| D&A | 12.1M | 12.4M | 12.2M | 7.2M | 7.0M |
| EBIT | (205.9M) | (197.5M) | 22.2M | (96.2M) | 43.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026